

Shanu Modi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/683008/publications.pdf>

Version: 2024-02-01

92
papers

10,272
citations

53794

45
h-index

46799

89
g-index

92
all docs

92
docs citations

92
times ranked

10150
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 165-182.	329.8	132
2	Refractive Shifts and Changes in Corneal Curvature Associated With Antibody–Drug Conjugates. <i>Cornea</i> , 2022, 41, 792-801.	1.7	6
3	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
4	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 387, 9-20.	27.0	854
5	Beyond HER2: Targeting the ErbB receptor family in breast cancer. <i>Cancer Treatment Reviews</i> , 2022, 109, 102436.	7.7	13
6	Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. <i>CNS Oncology</i> , 2022, 11, .	3.0	4
7	Unlocking the potential of antibody–drug conjugates for cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 327-344.	27.6	498
8	A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with <i>PIK3CA</i> -Mutated HER2-Positive Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3867-3875.	7.0	15
9	Abstract CT167: Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. <i>Cancer Research</i> , 2021, 81, CT167-CT167.	0.9	11
10	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	9.4	222
11	Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. <i>Breast Cancer Research</i> , 2021, 23, 84.	5.0	108
12	Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study. <i>Future Oncology</i> , 2021, 17, 3415-3423.	2.4	17
13	Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates. <i>JAMA Oncology</i> , 2021, 7, 1873.	7.1	66
14	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 610-621.	27.0	1,143
15	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5588-5597.	7.0	7
16	Reply to T.J.A. Dekker. <i>Journal of Clinical Oncology</i> , 2020, 38, 3351-3352.	1.6	0
17	Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. <i>Clinical Cancer Research</i> , 2020, 26, 5609-5620.	7.0	32
18	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5178-5187.	7.0	18

#	ARTICLE	IF	CITATIONS
19	Dermatologic adverse events related to the PI3KÎ± inhibitor alpelisib (BYL719) in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 227-237.	2.5	22
20	Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. <i>Cell Reports</i> , 2020, 31, 107840.	6.4	32
21	Antitumor Activity and Safety of Trastuzumab Deruxtecán in Patients With HER2-Lowâ€“Expressing Advanced Breast Cancer: Results From a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1887-1896.	1.6	465
22	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. <i>Nature Cancer</i> , 2020, 1, 382-393.	13.2	96
23	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2âˆ“ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6417-6428.	7.0	11
24	Measuring Tumor Epichaperome Expression Using [¹²⁴ I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1414-1424.	3.0	13
25	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 559-573.e7.	16.8	40
26	Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up. <i>Oncologist</i> , 2019, 24, e646-e652.	3.7	5
27	Trastuzumab deruxtecán (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 827-836.	10.7	154
28	Trastuzumab deruxtecán (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 816-826.	10.7	252
29	Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia. <i>JAMA Dermatology</i> , 2019, 155, 724.	4.1	46
30	Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer. <i>JAMA Network Open</i> , 2019, 2, e1916211.	5.9	7
31	Chaperome heterogeneity and its implications for cancer study and treatment. <i>Journal of Biological Chemistry</i> , 2019, 294, 2162-2179.	3.4	37
32	Copper-64 trastuzumab PET imaging: a reproducibility study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 191-198.	0.7	21
33	Endocrine Therapyâ€“Induced Alopecia in Patients With Breast Cancer. <i>JAMA Dermatology</i> , 2018, 154, 670.	4.1	71
34	Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 387-394.	2.4	37
35	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2804-2807.	1.6	93
36	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2736-2740.	1.6	141

#	ARTICLE	IF	CITATIONS
37	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. <i>Cancer Cell</i> , 2018, 34, 427-438.e6.	16.8	633
38	Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. <i>Oncologist</i> , 2017, 22, 139-143.	3.7	27
39	Targeting HER2/3 in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 61-69.	1.0	0
40	Triplet Combination of Endocrine Therapy with CDK 4/6 Inhibitor, Ribociclib, and MTOR Inhibitor, Everolimus in HR+, HER2-ABC: Results from the Dose-Expansion Cohort. <i>Breast</i> , 2017, 36, S46-S47.	2.2	0
41	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2017, 19, 89.	5.0	45
42	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401.	27.8	233
43	Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , 2016, 18, 34.	5.0	34
44	A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 87-94.	2.4	1
45	Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors. <i>Clinical Breast Cancer</i> , 2016, 16, 276-283.	2.4	11
46	Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. <i>Discovery Medicine</i> , 2016, 21, 65-74.	0.5	59
47	Ganetespib: research and clinical development. <i>OncoTargets and Therapy</i> , 2015, 8, 1849.	2.0	62
48	Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 442-447.	1.6	75
49	The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. <i>Annals of Surgical Oncology</i> , 2015, 22, 495-501.	1.5	44
50	Phase I trial of the HSP-90 inhibitor PU-H71.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2537-2537.	1.6	7
51	A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 154-160.	2.4	91
52	Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 451-456.	2.5	25
53	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2100-2108.	1.6	165
54	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 2078-2099.	1.6	303

#	ARTICLE	IF	CITATIONS
55	Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions. Expert Opinion on Investigational Drugs, 2014, 23, 611-628.	4.1	146
56	Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics. Journal of Visualized Experiments, 2014, , e52157.	0.3	8
57	A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer. Breast Cancer Research and Treatment, 2013, 139, 107-113.	2.5	61
58	Pilot study of ⁶⁸ Ga-DOTA-F(ab ²) ₂ -trastuzumab in patients with breast cancer. Nuclear Medicine Communications, 2013, 34, 1157-1165.	1.1	68
59	Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer. Cancer Prevention Research, 2013, 6, 428-436.	1.5	65
60	Using ¹²⁴ I-PU-H71 PET imaging to predict intratumoral concentration in patients on a phase I trial of PU-H71.. Journal of Clinical Oncology, 2013, 31, 11076-11076.	1.6	5
61	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology, 2012, 30, 3234-3241.	1.6	319
62	Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer. Clinical Cancer Research, 2012, 18, 6784-6791.	7.0	176
63	HSP90 Inhibitors for Cancer Therapy and Overcoming Drug Resistance. Advances in Pharmacology, 2012, 65, 471-517.	2.0	69
64	Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2â€“Targeted Antibodyâ€“Drug Conjugate, in Patients With HER2â€“Positive Metastatic Breast Cancer. Journal of Clinical Pharmacology, 2012, 52, 691-703.	2.0	61
65	A Phase I Dose-Escalation Trial of Trastuzumab and Alveespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors. Clinical Cancer Research, 2012, 18, 5090-5098.	7.0	58
66	A phase 1 study of weekly dosing of trastuzumab emtansine (Tâ€“DM1) in patients with advanced human epidermal growth factor 2â€“positive breast cancer. Cancer, 2012, 118, 5733-5740.	4.1	88
67	Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 742-755.	4.1	384
68	Biomarkers that predict sensitivity to heat shock protein 90 inhibitors (HSP90i).. Journal of Clinical Oncology, 2012, 30, 10618-10618.	1.6	3
69	Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opinion on Drug Discovery, 2011, 6, 559-587.	5.0	87
70	A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicinâ€“Cyclophosphamide (AC) Followed by Nanoparticle Albuminâ€“Bound Paclitaxel in Early-Stage Breast Cancer. Clinical Cancer Research, 2011, 17, 3398-3407.	7.0	28
71	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research, 2011, 17, 5132-5139.	7.0	396
72	A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Annals of Oncology, 2011, 22, 2575-2581.	1.2	49

#	ARTICLE	IF	CITATIONS
73	Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can There Be Too Many Active Drugs?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3111-3113.	1.6	3
74	Intravenous Bisphosphonate Therapy Does Not Acutely Alter Nuclear Bone Scan Results. <i>Clinical Breast Cancer</i> , 2010, 10, 33-39.	2.4	8
75	Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 2698-2704.	1.6	535
76	HER2 breast cancer therapies: a review. <i>Biologics: Targets and Therapy</i> , 2009, , 289.	3.2	25
77	HER2 breast cancer therapies: a review. <i>Biologics: Targets and Therapy</i> , 2009, 3, 289-301.	3.2	45
78	The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target. <i>Current Cancer Drug Targets</i> , 2008, 8, 522-535.	1.6	50
79	Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER2-Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 5410-5417.	1.6	333
80	Preoperative Chemotherapy for Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2665.	7.4	13
81	A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2006, 7, 270-277.	2.4	86
82	Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. <i>Cancer</i> , 2005, 104, 1575-1579.	4.1	167
83	A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 157-163.	2.5	84
84	Combination versus sequential single-agent therapy for the treatment of metastatic breast cancer. <i>European Journal of Cancer, Supplement</i> , 2005, 3, 3-8.	2.2	4
85	Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer. <i>Cancer Investigation</i> , 2005, 23, 483-487.	1.3	37
86	A Phase II Trial of Gemcitabine in Patients with Metastatic Breast Cancer Previously Treated with an Anthracycline and Taxane. <i>Clinical Breast Cancer</i> , 2005, 6, 55-60.	2.4	48
87	Single-Agent Gemcitabine in the Treatment of Advanced Breast Cancer. <i>Clinical Breast Cancer</i> , 2004, 4, S101-S106.	2.4	12
88	Prospective Exploratory Analysis of the Association Between Tumor Response, Quality of Life, and Expenditures Among Patients Receiving Paclitaxel Monotherapy for Refractory Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3665-3673.	1.6	28
89	An update on epidermal growth factor receptor inhibitors. <i>Current Oncology Reports</i> , 2002, 4, 47-55.	4.0	26
90	Biomonitoring of urinary tamoxifen and its metabolites from breast cancer patients using nonaqueous capillary electrophoresis with electrospray mass spectrometry. <i>Electrophoresis</i> , 2001, 22, 2730-2736.	2.4	35

#	ARTICLE	IF	CITATIONS
91	Phase I Study of the BLP25 (MUC1 Peptide) Liposomal Vaccine for Active Specific Immunotherapy in Stage IIIB/IV Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2001, 3, 49-57.	2.6	145
92	The cancer patient with chronic pain due to herpes zoster. <i>Current Review of Pain</i> , 2000, 4, 429-436.	0.7	4